| First Author | Oosterlaken TA | Year | 1991 |
| Journal | J Virol | Volume | 65 |
| Issue | 1 | Pages | 98-102 |
| PubMed ID | 1845911 | Mgi Jnum | J:27005 |
| Mgi Id | MGI:74423 | Doi | 10.1128/jvi.65.1.98-102.1991 |
| Citation | Oosterlaken TA, et al. (1991) A protective monoclonal anti-idiotypic vaccine to lethal Semliki Forest virus infection in BALB/c mice. J Virol 65(1):98-102 |
| abstractText | Two monoclonal anti-idiotypic antibodies (ab2 MAbs), designated 1.13A112 (immunoglobulin G type 2a [IgG2a]) and 1.13A321 (IgG1), were prepared against Semliki Forest virus (SFV)-neutralizing ab1 MAb UM 1.13. They were identified in hybridoma supernatant fluid by their capacity to block UM 1.13-mediated neutralization of SFV. Although the neutralization-blocking capacities of the ab2 MAbs did not differ, only 1.13A321 evoked SFV-neutralizing ab3 antibodies upon intracutaneous and subcutaneous immunization of BALB/c mice with 1.13A321 chemically cross-linked to keyhole limpet hemocyanin and combined with the adjuvant Quil A. SFV-neutralizing ab3 antibodies appeared in serum within 10 days after primary immunization, and neutralizing antibody titers could be as high as 1/1,000 at day 35. All mice who had developed SFV-neutralizing antibodies upon anti-idiotypic immunization survived an otherwise lethal challenge with virulent SFV. However, induction of SFV-neutralizing ab3 antibodies by ab2 MAb 1.13A321 proved to be genetically restricted to BALB/c mice; even haplotype-identical (H-2d) DBA/2 mice did not respond, and consequently those animals died after infection with virulent SFV. |
